Matthew During News Today

Ovid Therapeutics Inc. (NASDAQ:OVID – Get Rating) was the recipient of a significant increase in short interest in May. As of May 31st, there was short interest totalling 414,500 shares, an increase of 28.7% from the May 15th total of 322,100 shares. Currently, 0.7% of the shares of the stock are sold short. Based on […]

Ovid Therapeutics Inc. (NASDAQ:OVID – Get Rating) traded up 0.9% during mid-day trading on Wednesday . The company traded as high as $3.55 and last traded at $3.48. 53,116 shares changed hands during trading, a decline of 39% from the average session volume of 87,693 shares. The stock had previously closed at $3.45. Wall Street […]

Ovid Therapeutics Inc. (NASDAQ:OVID – Get Rating)’s share price was up 0.3% during mid-day trading on Wednesday . The company traded as high as $3.65 and last traded at $3.61. Approximately 129,235 shares traded hands during mid-day trading, an increase of 68% from the average daily volume of 77,129 shares. The stock had previously closed […]

Ovid Therapeutics Inc. (NASDAQ:OVID – Get Rating) was up 6.6% during trading on Wednesday . The stock traded as high as $2.96 and last traded at $2.92. Approximately 116,459 shares changed hands during mid-day trading, an increase of 74% from the average daily volume of 66,949 shares. The stock had previously closed at $2.74. Wall […]

Acerus Pharmaceuticals (OTCMKTS:ASPCF – Get Rating) and Ovid Therapeutics (NASDAQ:OVID – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends. Analyst Ratings This is a breakdown of current ratings […]

Zacks Investment Research cut shares of Ovid Therapeutics (NASDAQ:OVID – Get Rating) from a buy rating to a hold rating in a research report sent to investors on Saturday, Zacks.com reports. According to Zacks, “Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders. The company’s product […]

Ovid Therapeutics (NASDAQ:OVID – Get Rating) released its quarterly earnings results on Tuesday. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.22), MarketWatch Earnings reports. NASDAQ:OVID opened at $3.13 on Wednesday. The firm has a market cap of $213.13 million, a PE ratio of 1.75 and […]

Equities research analysts forecast that Ovid Therapeutics Inc. (NASDAQ:OVID – Get Rating) will announce earnings of ($0.17) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Ovid Therapeutics’ earnings. Ovid Therapeutics reported earnings of ($0.34) per share during the same quarter last year, which suggests a positive […]

Novavax, Inc Novavax, Inc. is a clinical-stage vaccine company that focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. With the onset of the global pandemic last year, the company has also ventured into making COVID-19 vaccines. Despite not having any product in the market yet and facing delays in production, it is still expected to be one of the leading vaccine candidates. The company’s vaccine has proven to be just as potent as o...

Press release content from Business Wire. The AP news staff was not involved in its creation. Matthew During, M.D., Ph.D. to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics April 26, 2021 GMT BROOKLYN, N.Y.--(BUSINESS WIRE)--Apr 26, 2021-- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced the appointment of Matt...